Follow us:

Xarelto Bellwether Trials Set to Begin in 2017

Posted on

A series of Xarelto bellwether trials may begin as soon as February 2017, according to a Case Management Order issued on September 17 by the U.S. District Court, Easter District of Louisiana.

Xarelto-pill_MainThe cases are part of a federal multidistrict litigation (MDL) established in December 2014 to consolidate product liability complaints filed in federal court involving bleeding problems with the anticoagulant drug Xarelto. Early bellwether trials are commonly conducted to further the efficient progress of litigation.

Although the outcomes of these trials will not specifically be binding upon other lawsuits, these cases will be tried to help the parties gauge how juries might respond to certain evidence and testimony that will likely be presented throughout the litigation. Pursuant to the Order, the first two trials will take place in the Eastern District of Louisiana in February and March 2017, and the others to follow in Mississippi in April and Texas in May, districts to be determined.

Xarelto Benefits and Risks

Xarelto was approved by the U.S. Food and Drug Administration (FDA) in November 2011 to reduce the risk of stroke and blood clots associated with non-valvular atrial fibrillation, to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of DVT and PE in patients undergoing knee or hip replacement surgery. It works by inhibiting the enzyme in the blood that causes it to clot, but with no approved antidote available that will quickly reduce Xarelto’s blood thinning effects, serious and even fatal bleeding events have occurred among the medication’s users.

Xarelto Lawsuit Allegations

The Xarelto lawsuits all involve similar allegations: the failure on the part of the drug’s makers, Janssen Research and Development and Bayer Healthcare Pharmaceuticals, to provide adequate warnings about the potential side effects of Xarelto, which include irreversible brain and gastrointestinal bleeding and uncontrollable hemorrhaging.

Similar to other anticoagulants, the Xarelto label contains warnings about the medication’s potential risk of bleeding events, but the lawsuits allege that the information provided is insufficient and fails to convey the serious and potentially deadly nature of the medication’s side effects.

If you or a loved one has suffered serious, uncontrollable bleeding while on Xarelto, you should speak with Childers, Schlueter & Smith today about seeking compensation. Led by firm partner Andy Childers, our Xarelto injury lawyers can help you understand your legal rights and seek redress for your injuries. It may be the only way to alleviate the financial hardship that has been placed upon you.

Tags: , , , , , , , , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.